Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Polygenic Hazard Score Predicts Synaptic and Axonal Degeneration and Cognitive Decline in Alzheimer's Disease Continuum Publisher Pubmed



Farhadieh ME1 ; Mozafar M2, 3 ; Sanaaee S4 ; Sodeifi P5 ; Kousha K6 ; Zare Y7 ; Zare S8 ; Maleki Rad N9 ; Jamshidigoharrizi F10, 11 ; Allahverdloo M12 ; Rahimi A13 ; Sadeghi M2, 3 ; Shafie M2, 3 ; Mayeli M14
Authors

Source: Archives of Gerontology and Geriatrics Published:2024


Abstract

Background: Growth associated protein-43 (GAP-43) and neurofilaments light (NFL) are biomarkers of synaptic and axonal injury, and are associated with cognitive decline in Alzheimer's disease (AD) contiuum. We investigated whether Polygenic Hazard Score (PHS) is associated with specific biomarkers and cognitive measures, and if it can predict the relationship between GAP-43, NFL, and cognitive decline in AD. Method: We enrolled 646 subjects: 93 with AD, 350 with mild cognitive impairment (MCI), and 203 cognitively normal controls. Variables included GAP-43, plasma NFL, and PHS. A PHS of 0.21 or higher was considered high risk while a PHS below this threshold was considered low risk. A subsample of 190 patients with MCI with four years of follow-up cognitive assessments were selected for longitudinal analysis . We assessed the association of the PHS with AD biomarkers and cognitive measures, as well as the predictive power of PHS on cognitive decline and the conversion of MCI to AD. Results: PHS showed high diagnostic accuracy in distinguishing AD, MCI, and controls. At each follow-up point, high risk MCI patients showed higher level of cognitive impairment compared to the low risk group. GAP-43 correlated with all follow-up cognitive tests in high risk MCI patients which was not detected in low risk MCI patients. Moreover, high risk MCI patients progressed to dementia more rapidly compared to low risk patients. Conclusion: PHS can predict cognitive decline and impacts the relationship between neurodegenerative biomarkers and cognitive impairment in AD contiuum. Categorizing patients based on PHS can improve the prediction of cognitive outcomes and disease progression. © 2024
Related Docs
View other Related Docs
1. Potential Mediating Role of Polygenic Hazard Score in the Association Between Neurofilament Light Chain and Default Mode Network Connectivity Across the Alzheimer's Disease Continuum, IBRO Neuroscience Reports (2025)
2. Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions, Journal of Neuropathology and Experimental Neurology (2019)
3. Plasma Neurofilament Light Levels Correlate With White Matter Damage Prior to Alzheimer’S Disease: Results From Adni, Aging Clinical and Experimental Research (2022)
Experts (# of related papers)
View all Related Experts
Abbas Tafakhori (1)
Vajiheh Aghamollaii (1)
Other Related Docs
4. The Polygenic Hazard Score Mediates the Association Between Plasma Neurofilament Light Chain and Brain Morphometry in Dementia Spectrum, Archives of Gerontology and Geriatrics (2025)
5. Growth-Associated Protein 43 and Tensor-Based Morphometry Indices in Mild Cognitive Impairment, Neuroinformatics (2024)
6. Growth Associated Protein 43 (Gap-43) Predicts Brain Amyloidosis in Alzheimer’S Dementia Continuum: An [18 F] Av-45 Study, BMC Neurology (2025)
7. Plasma Neurofilament Light Chain Associated With Impaired Regional Cerebral Blood Flow in Healthy Individuals, Current Journal of Neurology (2023)
8. Altered Brain Connectivity in Mild Cognitive Impairment Is Linked to Elevated Tau and Phosphorylated Tau, But Not to Gap-43 and Amyloid-Β Measurements: A Resting-State Fmri Study, Molecular Brain (2024)
9. Investigating the Association Between the Gap-43 Concentration With Diffusion Tensor Imaging Indices in Alzheimer’S Dementia Continuum, BMC Neurology (2024)
10. Elevated Serum Leucine Levels Are Associated With Cognitive Impairment and Reduced Gray Matter and Cerebral Volume Across the Alzheimer's Disease Continuum, Neuroscience (2025)
11. A Comprehensive Investigation of the Associations Between Tensor-Based Morphometry Indices and Executive Functions, Memory, Language, and Visuospatial Abilities in Patients in the Alzheimer's Disease Continuum, Clinical Neurology and Neurosurgery (2024)
12. Associations Between Diffusion Tensor Imaging Patterns and Cerebrospinal Fluid Markers in Mild Cognitive Impairment, Journal of Clinical Neuroscience (2025)
13. Biological Features of Reversion From Mild Cognitive Impairment to Normal Cognition: A Study of Cerebrospinal Fluid Markers and Brain Volume, Journal of Alzheimer's Disease Reports (2021)
14. Growth-Associated Protein 43 Levels in the Cerebrospinal Fluid Correspond to the Cerebral Blood Flow Alterations in Alzheimer's Dementia Continuum: An Original Study, Health Science Reports (2025)
15. A Comprehensive Investigation of the Associations Between Cerebral Blood Flow and Cerebrospinal Fluid Biomarkers Across the Alzheimer's Disease Continuum, Clinical Neurology and Neurosurgery (2025)
16. Do Serum Gdnf Levels Correlate With Severity of Alzheimer’S Disease?, Neurological Sciences (2021)
17. A Comprehensive Investigation of the Potential Role of Lipoproteins and Metabolite Profile As Biomarkers of Alzheimer's Disease Compared to the Known Csf Biomarkers, International Journal of Alzheimer's Disease (2023)
18. Evaluating the Predictive Value of Oxylipins for Cognitive Measures And White Matter Hyperintensities in Alzheimer’S Disease Continuum Compared to Conventional Beta‑Amyloid and Tau Protein Biomarkers, Molecular Neurobiology (2025)
19. A Novel Approach to Type 3 Diabetes Mechanism: The Interplay Between Noncoding Rnas and Insulin Signaling Pathway in Alzheimer's Disease, Journal of Cellular Physiology (2022)
20. Baseline Brain Volumes Predict Future Brain Atrophy in Mild Cognitive Impairment: A Tensor-Based Morphometry Study of the Alzheimer Continuum, Journal of Computer Assisted Tomography (2025)